Sector News

Roche buys German genomics group Signature

February 10, 2015
Life sciences
Roche has hit the acquisition trail again to buy privately-held Signature Diagnostics of Germany.
 
The Potsdam-based firm is a translational oncology and genomics company that develops large blood plasma and tissue biobanks in multiple cancers, including colorectal and lung. Signature uses the samples from its biobanks along with accompanying clinical progression and genetic data to develop and validate circulating cell free DNA (cfDNA) tests.
 
Roche says these tests have the potential to advance non-invasive treatment response monitoring for patients with cancer. Roland Diggelmann, head of its diagnostics unit, stated that biobanks play an important role in aiding translational research and the development of personalised therapies for patients.
 
He added that Signature “represents a unique bridge between high value cancer biobanks and next generation sequencing (NGS) assay development”. The German group will be integrated into Roche Sequencing Unit, which has grown through the recent acquisitions of Bina Technologies and Genia Technologies.
 
Financial terms have not been disclosed.
 
By Kevin Grogan
 
Source: Pharma Times

comments closed

Related News

June 24, 2022

Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH

Life sciences

Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders.

June 24, 2022

argenx receives positive CHMP opinion for Efgartigimod for the treatment of adult patients with Generalized Myasthenia Gravis in Europe

Life sciences

Positive opinion based on Phase 3 ADAPT trial showing efgartigimod provided clinically meaningful improvements in strength and quality of life measures. If approved, efgartigimod will be the first neonatal Fc receptor (FcRn) blocker for the treatment of adults in Europe living with rare neuromuscular disease generalized myasthenia gravis (gMG).

June 24, 2022

Galapagos finally takes M&A plunge, spending $251M for 2 biotechs in CAR-T push

Life sciences

Galapagos CEO Paul Stoffels, M.D., has finally taken the plunge on M&A. The newly minted chief executive has signed not one but two deals in an attempt to right the ship, bringing two small biotechs aboard for a combined 239 million euros ($251.4 million).